When creating groundbreaking health care technology, keeping products user friendly is a necessity. Photo via Getty Images

In the vibrant landscape of startups, the quest to build groundbreaking products can sometimes overshadow the true essence of our existence — to solve problems for our customers.

It's a trap many fall into, often leading to two common outcomes: prolonged product launches stretching over years or an unfortunate mismatch between product and market leading to startup death. But a dynamic solution exists, minimum viable products, or MVPs. MVP has propelled startups to unprecedented success.

A real-life testimony: MVP's power

Imagine a health care-focused at-home testing startup partnered with a major player. The aim: a telehealth support system for the at-home colon cancer screening. Unlike traditional telehealth services, this system required guiding members through a complex process of collecting stool samples accurately.

Challenges presented

  • Develop a user-friendly telehealth solution in five to six weeks on a limited budget and secure a high-stakes multimillion-dollar deal.
  • Carefully integrating telehealth on the existing portal for user-friendly access while aligning seamlessly with user expectations.
  • Address the complexities of Telehealth, including clinician staffing and regulatory adherence.

User Insights

User journeys and interviews confirmed the necessity for guided support during test-taking, but users showed reluctance to navigate the process independently and expressed a preference for customer support over a clinician assistant.

Interestingly, telehealth was not instinctively linked to test support, but rather to medical advice.

The birth of an MVP strategy: a catalyst for innovation

Since the main user problem was the guided support during test-taking, we created the following MVP solutions.

  • Video call integration: Direct video call button under customer support.
  • Guided messaging: Articulate call support purpose.
  • Testing guides: Portal's step-by-step guidance with videos.
  • Video guide in test kit materials.

Our MVP led us to an excellent NPS score and became a guide for our future roadmap.

Next time you build, remember this and embrace the dynamic MVP strategy — create, learn, and reiterate are the cornerstones of success in digital health product management's journey.

Here are four steps for building a successful MVP in telehealth.

  • Identify crucial user problems: Pinpoint your target customers' most pressing issue.
  • Solve a small problem simply: Initiate a straightforward solution to address a minor problem.
  • Plot the user's journey: Map out the user's path through your solution.
  • Prioritize ruthlessly: Discern the key features and prioritize with precision.
------

Tanu Jain is the founder and CEO of Houston-based Digital Health Innovator, a strategic marketing firm for health care products.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

European spacecraft developer expands to Houston with U.S. business, new lab

houston hq

European aerospace manufacturer The Exploration Company has established its first U.S. entity and named Space City as its headquarters.

The company announced earlier this month that it has launched TEC Federal to support U.S. government customers and agencies, and to scale The Exploration Company's engineering operations in the country.

Mark Kirasich serves as president of TEC Federal. Kirasich most recently served as the senior director of human spaceflight at Blue Origin after a nearly 40-year career at NASA.

The Exploration Company is developing the reusable Nyx space vehicle. Nyx is designed to take off from any heavy launcher in the world. It will then dock at space stations, retrieve up to 3,000 kilograms of cargo, splash down and return the cargo to Earth. The company aims to make Nyx fully reusable for up to 10 missions, making it a more affordable and sustainable option for aerospace missions.

The Exploration Company completed a successful drop test of the spacecraft in May in the Mojave Desert. The company says Nyx is slated to perform its first flight demonstration in 2028.

In addition to launching the Houston business, The Exploration Company also opened its new Rapid Innovation Lab near Houston's NASA Johnson Space Center on Space Park Drive.

The Exploration Company opened its Rapid Innovation Lab earlier this month. Photo via LinkedIn

The Rapid Innovation Lab features a full-scale mockup of the future Nyx crew capsule as well as ongoing development and testing of the Nyx cargo capsule, according to the company.

The Exploration Company says the new lab will allow its engineers, designers, and operators to prototype and test crew interfaces. It will also support partnerships with NASA personnel and astronauts.

“Houston gives us direct access to the people and expertise that have built and operated human spaceflight systems for decades. We’re excited to invest and expand around that— engineers, operators, and astronauts working together and moving quickly towards building a crew capsule.” Hélène Huby, founder and CEO of The Exploration Company, said in a blog post.

According to The Houston Chronicle, The Exploration Company has about 30 employees in the Houston area.

The company was founded in 2021 by Huby, a French rocket scientist, and has raised more than $350 million in venture capital. It operates out of Germany, France, Luxembourg, Spain and Italy, with offices in the U.S. and the United Arab Emirates. It is also developing a reusable, high-thrust rocket engine known as Storm.

UH lands $4M NIH grant to study early signs of autoimmune disease

NIH funding

The University of Houston recently received a $4 million National Institutes of Health grant to support a 10-year longitudinal study to identify the earliest biological markers of autoimmune disease.

Led by Chandra Mohan, the Hugh Roy and Lillie Cranz Cullen Endowed Professor of Biomedical Engineering, the study aims to examine what causes Systemic Autoimmune Rheumatic Diseases (SARDs) and to identify targets for future treatments. The study will be carried out in collaboration with Dr. Karen Costenbader at Harvard Medical School, Boston.

SARDs include conditions like rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s syndrome and systemic sclerosis—all are considered chronic diseases currently without a cure. Autoimmune diseases affect over 30 million people globally, according to UH.

SARDs occur when the body’s immune system attacks healthy, non-threatening tissues and organs. According to UH, in these diseases, the body often attacks nuclear antigens, creating anti-nuclear autoantibodies, which can be early detection signs for SARDs in more than 50 percent of patients, Mohan says.

Researchers will study blood samples and environmental exposure over the 10 years to better understand anti-nuclear autoantibodies.

“Collectively, these studies will help identify the genetic, environmental and cellular factors that are operative at the two steps of SARD development, namely the emergence of anti-nuclear autoantibodies and disease onset,” Mohan said in a news release. “ More importantly, these studies will highlight functional molecular pathways and mechanisms that may be operative at each step."

Mohan predicts that looking at SARDs’ shared characteristics, rather than each disease individually, could help identify more treatment methods.

“Individual SARDs have been examined in silos without an attempt to discern shared underlying features at the molecular level,” he added in the release. “Current understanding of the initial (and likely shared) origins of SARDs is only rudimentary but urgently needed to develop means for prevention and treatment.”

Earlier this year, UH also received an $11 million NIH grant to conduct a first-of-its-kind study of early language development in children ages 18 to 24 months. Read more here.